Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02613091 · ClinicalTrials.gov registry record · Phase 1
Effect of Clemastine Fumarate on Color Vision in Healthy Controls
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02613091 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 23 participants.
The verdict
NCT02613091, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
In a1972 study in the French Annals of Pharmaceuticals, Laroche and Laroche reported that the drug clemastine has a negative effect on patients' color discrimination, which is the ability to distinguish different hues and arrange them in the correct order. In an upcoming clinical trial studying the effect of clemastine on vision outcomes, our lab aims to assess color visual performance adding assessment of color defectiveness as a clinical endpoint. Color defectiveness is the ability to see certain colors, and is commonly referred to as color-blindness. Color discrimination and defectiveness can be related, but do not always correlate. This study aims to detect the effect, if any, that clemastine has on color defectiveness in healthy controls, which could confound its use as an outcome endpoint in future clinical trials relating to clemastine.
Interventions
- DRUG Clemastine fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02613091
The ClinicalTrials.gov registry entry for NCT02613091 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Clemastine fumarate is the first listed.
NCT02613091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02613091 about?
NCT02613091 is a clinical study titled "Effect of Clemastine Fumarate on Color Vision in Healthy Controls". In a1972 study in the French Annals of Pharmaceuticals, Laroche and Laroche reported that the drug clemastine has a negative effect on patients' color discrimination, which is the ability to distinguish different hues and arrange them in the correct order. In an upcoming clinical trial studying the ...
What is the current status of trial NCT02613091?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-04.
What interventions are being tested in trial NCT02613091?
The interventions under investigation include: Clemastine fumarate (DRUG).
Who is sponsoring clinical trial NCT02613091?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.